Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Proteoglycans01:05

Proteoglycans

Glycans, a class of complex heterogeneous molecules, can be covalently attached to proteins to form glycosylated proteins that regulate various physiological and pathological processes. Glycosylated proteins or glycoproteins comprise N-linked and O-linked oligosaccharides. O-glycosylation is the most common type of protein glycosylation. Here, glycans attach to the oxygen atom of the hydroxyl groups of Serine or Threonine residues. O-linked glycosylation occurs later in protein processing,...
Oligosaccharide Assembly01:24

Oligosaccharide Assembly

Protein glycosylation starts in the ER lumen and continues in the Golgi apparatus. Glycosyltransferases catalyze the addition of sugar molecules or glycosylation of proteins. Usually, these enzymes add sugars to the hydroxyl groups of selected serine or threonine residues to form O-linked glycans or the amino groups of asparagine residues to form N-linked glycans. Different positions on the same polypeptide chain can contain differently linked glycans.
Multiple sugar molecules that may or may...
Protein Glycosylation01:25

Protein Glycosylation

Glycosylation, the most common post-translational modification for proteins, serves diverse functions. Adding sugars to proteins makes the proteins more resistant to proteolytic digestion. Glycosylated proteins can act as markers and receptors to promote cell-cell adhesion. Additionally, they have many essential quality control functions in the cell, such as correct protein folding and facilitating transport of misfolded proteins to the cytosol, which can be degraded.
Glycosylation occurs in...
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeting Dental Pulp Stem Cell Senescence: A Potential Strategy for Improving Regenerative Endodontic Procedures.

Bioengineering (Basel, Switzerland)·2026
Same author

Mapping ST3GAL transferase specificities in the glycosylation landscape of N/TERT-1 keratinocytes using Glycogenomics and mass spectrometry.

Glycobiology·2026
Same author

EatA mediated degradation of intestinal mucus is species-specific and driven by MUC2 structural features.

Nature communications·2025
Same author

Multiplexed Detection of Autoantibodies to Glycopeptides Using Microarray.

Methods in molecular biology (Clifton, N.J.)·2025
Same author

Influence of Distinct Maternal Cytomegalovirus-Specific Neutralizing and Fc Receptor-Binding Responses on Congenital Cytomegalovirus Transmission in HIV-Exposed Neonates.

Viruses·2025
Same author

Twin Prime Editing Mediated Exon Skipping/Reinsertion for Restored Collagen VII Expression in Recessive Dystrophic Epidermolysis Bullosa.

The Journal of investigative dermatology·2024
Same journal

Cell Surface Glycans: From Recognition Technologies and Functional Editing to Medical Applications.

Glycobiology·2026
Same journal

Aberrant O-glycosylation genes and miR-21-5p targets define a molecular signature of tumor aggressiveness in triple-negative breast cancer.

Glycobiology·2026
Same journal

Glyco you should know.

Glycobiology·2026
Same journal

Biosynthesis of human milk oligosaccharides (HMOs) in glycoengineered human cells.

Glycobiology·2026
Same journal

Glyco you should know.

Glycobiology·2026
Same journal

Siglec-15 binds mucin-domain glycoproteins with extended glycans and marks an osteoclast-like, matrix remodeling myeloid state in human tumors.

Glycobiology·2026
See all related articles

Related Experiment Video

Updated: Jun 25, 2026

Glycan Node Analysis: A Bottom-up Approach to Glycomics
11:36

Glycan Node Analysis: A Bottom-up Approach to Glycomics

Published on: May 22, 2016

Cancer-Associated Alterations In O-GalNAc Glycosylation.

José Pires1, Eric Rochat1, Ieva Bagdonaite1

  • 1Copenhagen Center for Glycocalyx Research, Department of Cellular and Molecular Medicine, University of Copenhagen, Denmark.

Glycobiology
|June 24, 2026
PubMed
Summary
This summary is machine-generated.

Aberrant O-GalNAc glycans are key cancer antigens driving tumor progression and immune evasion. Novel therapies targeting these glycans, like antibody-drug conjugates, show promise for precision oncology.

Keywords:
cancerglycan binding proteinsglycoengineeringglycoproteomicstherapeutics

More Related Videos

Immunoglobulin G N-Glycan Analysis by Ultra-Performance Liquid Chromatography
11:01

Immunoglobulin G N-Glycan Analysis by Ultra-Performance Liquid Chromatography

Published on: January 18, 2020

Related Experiment Videos

Last Updated: Jun 25, 2026

Glycan Node Analysis: A Bottom-up Approach to Glycomics
11:36

Glycan Node Analysis: A Bottom-up Approach to Glycomics

Published on: May 22, 2016

Immunoglobulin G N-Glycan Analysis by Ultra-Performance Liquid Chromatography
11:01

Immunoglobulin G N-Glycan Analysis by Ultra-Performance Liquid Chromatography

Published on: January 18, 2020

Area of Science:

  • Oncology
  • Glycobiology
  • Immunology

Background:

  • Aberrant O-GalNAc glycans (Tn, STn, T) are tumor-associated antigens common in carcinomas but rare in healthy tissues.
  • Cancer-associated O-glycans present a heterogeneous mix of truncated and elongated structures influencing tumor hallmarks.
  • These glycans mediate interactions with glycan-binding proteins, impacting immune evasion and cancer progression.

Purpose of the Study:

  • To highlight the significance of aberrant O-GalNAc glycans in cancer.
  • To discuss their role in driving tumor formation and immune evasion.
  • To explore novel therapeutic strategies targeting these glycans.

Main Methods:

  • Review of existing literature on O-GalNAc glycans in cancer.
  • Analysis of the role of aberrant glycans in tumor hallmarks.
  • Evaluation of current and emerging therapeutic approaches.

Main Results:

  • Aberrant O-GalNAc glycans are consistently expressed in carcinomas and contribute to adhesion, signaling, dissemination, and immune evasion.
  • Truncated O-glycans are stable across cancer stages, making them attractive therapeutic targets.
  • O-glycan-directed therapies, including antibody-drug conjugates, demonstrate strong preclinical efficacy.

Conclusions:

  • Aberrant O-GalNAc glycans are crucial drivers of cancer progression and immune evasion.
  • Targeting these glycans offers a promising avenue for precision oncology.
  • Advancements in multi-specific antibodies, bio-orthogonal chemistry, and AI will refine safety, selectivity, and patient stratification for glycan-based therapies.